Galera completes acquisition of Nova Pharmaceuticals, files 8-K/A with SEC waiver for financial statements

Galera Therapeutics, Inc.

Acquisition of Nova Pharmaceuticals closed on Dec 30, 2024, via merger agreement.
SEC granted waiver from Rule 3-05 and Article 11, allowing omission of audited FY2023 and unaudited interim financials for 9 months ended Sep 30, 2023/2024.
Pro forma financial information also omitted under the waiver.
No deal value or terms disclosed in this filing; full financial impact not provided to investors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.